Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Abstract Objective The aim was to evaluate the cost-effectiveness of oral and subcutaneous semaglutide versus other oral glucose-lowering drugs (i.e., empagliflozin, canagliflozin, and sitagliptin) for the management of type 2 diabetes (T2D) in Denmark using clinically relevant treatment intensification rules
R., Fuse, K., Hahn, G., Schunkert, H., & Wang, S
Advanced Recomp Stack Storage & Handling Storage reference for all three compounds State Lyophilized (Powder) Retatrutide Room temp or refrigerated
Neurobiol Aging 1998
US$ 24.98
US$ 21.60
US$ 24.95
US$ 23.54
US$ 29.09
